L.E.K.’s Take on China Medtech: Optimistic Macro View, Short-Term Hit Hard Stephen Sunderland Read more
Related Practice MedTech Despite the COVID-19 lockdown, Stephen Sunderland foresees limited disruption 07102020100744
Case Study Life Sciences & Pharma Cost and Reimbursement Assessment for a Biopharmaceutical Company May 7, 2024 A large biopharmaceutical company developing chimeric antigen receptor T-cell (CAR-T) therapies
Article Life Sciences & Pharma Hospital Priorities in China in 2023: Strategic Implications for Pharma Companies December 7, 2023
Executive Insights Business Services Benefits of the 4-Day Week: The Jury Is Still Out October 31, 2023
Executive Insights Life Sciences & Pharma EUnetHTA 21 — Transition to EU-wide HTAs: Implications for Pharma July 31, 2023